Pipeline

NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer and neurodegenerative conditions.

SNK01, NKGen Biotech’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Product

Discovery

Preclinical

Phase I

Phase II

Phase III

SNK01


– Refractory Solid Tumors, Phase l
– Neurodegenerative Disease, Phase l

Refractory Solid Tumors
Neurodegenerative Disease

SNK01 +

pembrolizumab

– Stage IV Non-small Cell Lung Cancer, Phase ll

avelumab or pembrolizumab

– Refractory PD-L1+ AND PD-L1- Solid Tumors 2, Phase l

AFM24

– EGFR+ Solid Tumors, Phase l

Stage IV Non- Small Cell Lung Cancer
Refractory PD-L1+ and PD-L1- Solid Tumors *
EGFR+ Solid Tumors

Allogeneic SNK

Not Disclosed

Not Disclosed

CAR-SNK

Not Disclosed

Not Disclosed

* Following the data from our Phase 1 trial, with FDA consent, we expanded the Phase 1 trial to include a fourth cohort in refractory tumors with SNK in combination with avelumab or pembrolizumab.